1Y Close · As of Aug 26, 2026
Gencurix operates in the Pharmaceuticals sector.
Legal name: Gencurix Inc.
In fiscal year 2023, Gencurix (229000) reported revenue of 2.6 billion KRW, up 1.6% from 2.6 billion KRW a year earlier.
Operating profit was -11.2 billion KRW and net income was -20.1 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 42.4 billion KRW, with a P/B of 2.59.
These figures can be verified in the DART filing (receipt no. 20260316001142).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2023 | 2.6B | -11.2B | -20.1B |
| 2022 | 2.6B | -11.0B | -25.5B |
| 2021 | 3.0B | -12.7B | -35.1B |
Checks
2 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-25 | Stock Option Grant Report |
| 2026-08-25 | Meeting Notice |
| 2026-08-13 | Semi-Annual Report (2026.06) |